|
Females, n (%)
|
21/37 (56.8)
|
|
Age of the start TCZ, years
|
10.2 (6.0-12.8)
|
|
TCZ delay, months
|
36.0 (10.7-97.0)
|
|
SoJIA related symptoms at the start of TCZ, n (%)
| |
|
- fever
|
28 (75.7)
|
|
- rash
|
24 (73.0)
|
|
- hepatomegaly
|
20 (54.1)
|
|
- lymphadenopathy
|
13 (35.1)
|
|
- splenomegaly
|
11 (29.7)
|
|
- heart involvement
|
10 (27.0)
|
|
- interstitial lung disease
|
6 (16.2)
|
|
- CNS dysfunction
|
6 (16.2)
|
|
- coagulopathy with hemorrhage
|
4 (10.8)
|
|
Hemoglobin, g/dl
|
11.0 (10.3 – 12.1)
|
|
WBC, *109/l
|
11.9 (7.9 – 16.1)
|
|
Granulocytes, cells in 1 μl
|
7812.0 (5530.0 – 13202.0)
|
|
CRP, mg/l
|
35.0 (11.6 – 88.5)
|
|
ESR, mm/h
|
42.0 (22.0 – 54.0)
|
|
Platelets *109/l
|
361.0 (299.0 – 465.0)
|
|
Ferritin, mg/ml
|
197.0 (84.0 – 841.0)
|
|
LDH, U/l
|
513.0 (425.0 – 743.0)
|
|
Albumin, g/dl
|
3.0 (2.5 – 3.2)
|
|
Number of active joints at the start of TCZ
|
7.0 (2.0 – 22.0)
|
|
no active joints, n (%)
|
4 (10.8)
|
|
< 5 active joints, n (%)
|
13 (35.1)
|
|
≥5 active joints, n (%)
|
20 (54.1)
|
|
Treatment before TCZ administration:
| |
|
- Corticosteroids, n (%)
|
26 (70.3)
|
|
- mean dose, mg/kg
|
0,73
|
|
- Methotrexate, n (%)
|
32 (86.5)
|
|
- mean dose, mg/m2/week
|
14,7
|
|
- Cyclosporine A, n (%)
|
20 (54.1)
|
|
- mean dose, mg/kg
|
4,2
|
|
Combination
|
18 (48.7)
|
|
MAS before TCZ administration, n (%)
|
12 (32.4)
|
